Medical Therapy. Adverse Effects or Lack of Adverse Effects

Riociguat in children with pulmonary arterial hypertension: The PATENT-CHILD study

Humberto García Aguilar, Matthias Gorenflo, D. Dunbar Ivy, Shahin Moledina, Biagio Castaldi, Hidekazu Ishida, Paweł Cześniewicz, Jacek Kusa, Oliver Miera, Joseph Pattathu, Ken‐Pen Weng, Laszlo Ablonczy, Christian Apitz, Marta Katona, Kenichi Kurosaki, Tomas Pulido, Hiroyuki Yamagishi, Kazushi Yasuda, Galia Cisternas, Melanie Goth, Susanne Lippert, Anna Radomskyj, Soundos Saleh, Stefan Willmann, Gabriela Wirsching, Damien Bonnet, Maurice […]

Riociguat in children with pulmonary arterial hypertension: The PATENT-CHILD study Read More »

Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience

Azadeh Issapour, Benjamin Frank, Sarah Crook, Michelle D. Hite, Michelle L. Dorn, Erika B. Rosenzweig, D. Dunbar Ivy, Usha S. KrishnanColumbia University Irving Medical Center. University of Colorado and Children’s Hospital Colorado.United States Pediatric PulmonologyPediatr Pulmonol 2022; 57: 724-733DOI: 10.1002/ppul.25796 AbstractObjective: To describe the safety and tolerability of treatment with ambrisentan and tadalafil in pediatric pulmonary hypertension

Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience Read More »

Abnormal platelet aggregation in pediatric pulmonary hypertension

Stephanie S. Handler, Jing Jin, Michelle T. Ogawa, Jeffrey A. Feinstein, Clara LoMedical College of Wisconsin. Stanford University.United States Pulmonary CirculationPulm Circ 2022; 12: DOI: 10.1002/pul2.12104 AbstractEndogenous prostacyclin stimulates pulmonary vasodilation and inhibits platelet aggregation. For the synthetic analog treprostinil, used in the treatment of pulmonary hypertension (PH), conflicting, anecdotal evidence exists regarding its effects on

Abnormal platelet aggregation in pediatric pulmonary hypertension Read More »

Inpatient Transition From Intravenous to Inhaled Treprostinil in a Pediatric Patient

David Procaccini, Dennis Delany, Abigail Self, Patricia Lawrence Kane, John D. CoulsonJohns Hopkins HospitalUnited States Journal of Pediatric Pharmacology and TherapeuticsJ Pediatr Pharmacol Ther 2023; 28: 102-107DOI: 10.5863/1551-6776-28.1.102 AbstractWe report a case of a 7-year old male with idiopathic pulmonary arterial hypertension, successfully transitioned from an intravenous infusion to inhaled treprostinil during inpatient admission, after his

Inpatient Transition From Intravenous to Inhaled Treprostinil in a Pediatric Patient Read More »

Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience

David Edward Youssef, Stephanie S. Handler, Susan Marjorie Richards, Catherine Anne Sheppard, Jenna Smith, Kathryn Tillman, Matthew Pietrosanu, Edward Kirkpatrick, Angela Bates University of Alberta and Stollery Children’s Hospital. Medical College of Wisconsin.Canada and United States Frontiers in PediatricsFront Pediatr 2023; DOI: 10.3389/fped.2023.1055131 AbstractIntroduction: Phosphodiesterase type 5 (PDE5) inhibitors, with sildenafil the earliest among them, are widely used

Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience Read More »

Quantifying side effects and caregiver burdens of pediatric pulmonary hypertension therapies

Erik J. Nelson, Ella Cook, Samara Nelson, Rebecca Brown, Megan Pierce, Ashley Bangerter Seelos, Heather Stickle and Michael JohansenBrigham Young University. Utah State University. Indiana University School of Medicine. United States BioMed Central PediatricsBMC Pediatr 2023; 23: DOI: 10.1186/s12887-023-03860-2 AbstractBackground and objectives: Pulmonary hypertension (PH) is a rare, but serious disease among children. However, PH has been

Quantifying side effects and caregiver burdens of pediatric pulmonary hypertension therapies Read More »

Sotatercept for the Treatment of Pulmonary Arterial Hypertension

Marc Humbert, Vallerie McLaughlin, J. Simon R. Gibbs, Mardi Gomberg-Maitland, Marius M. Hoeper, Ioana R. Preston, Rogerio Souza, Aaron B. Waxman, Hossein-Ardeschir Ghofrani, Pilar Escribano Subias, Jeremy Feldman, Gisela Meyer, David Montani, Karen M. Olsson, Solaiappan Manimaran, Jennifer Barnes, Peter G. Linde, Janethe de Oliveira Pena, David B. BadeschPULSAR Trial Investigators.France, United States, United Kingdom,

Sotatercept for the Treatment of Pulmonary Arterial Hypertension Read More »

Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension

Marc Humbert, Vallerie McLaughlin, J. Simon R. Gibbs, Mardi Gomberg-Maitland, Marius M. Hoeper, Ioana R. Preston, Rogerio Souza, Aaron B. Waxman, Hossein-Ardeschir Ghofrani, Pilar Escribano Subias1, Jeremy Feldman, Gisela Meyer, David Montani, Karen M. Olsson, Solaiappan Manimaran, Janethe de Oliveira Pena, David B. BadeschHôpital Bicêtre, Assistance Publique-Hôpitaux de Paris. University of Michigan Health System. Imperial

Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension Read More »

Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension

Elizabeth Colglazier, Leah Stevens, Claire Parker, Hythem M. Nawaytou, Elena K. Amin, Jasmine Becerra, Martina Steurer, Jeffrey R. FinemanUniversity of California San FranciscoUnited States Pulmonary CirculationPulm Circ 2022; 12: DOI: 10.1002/pul2.12159 AbstractDespite the increase in therapeutic options, parenteral prostacyclins remain the cornerstone in the medical management of pulmonary arterial hypertension (PAH). While the use of parenteral

Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension Read More »

Systemic Sirolimus Therapy for Infants and Children With Pulmonary Vein Stenosis

Jay D. Patel, Michael Briones, Mansi Mandhani, Shannon Jones, Divya Suthar, Rosemary Gray, Joelle Pettus, Courtney McCraken, Amanda Thomas, Christopher J. PetitEmory University and Children’s Healthcare of AtlantaUnited States Journal of the American College of CardiologyJ Am Coll Cardiol 2021; 77: 2807-2818DOI: 10.1016/j.jacc.2021.04.013 AbstractBackground: Anatomic interventions for pulmonary vein stenosis (PVS) in infants and children have been

Systemic Sirolimus Therapy for Infants and Children With Pulmonary Vein Stenosis Read More »

Scroll to Top